BC Week In Review | Apr 13, 2018
Company News

pSivida acquires Icon, rebrands to EyePoint

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT; ASX:PVA) (formerly pSivida Corp.) acquired Icon Bioscience Inc. (Newark, Calif.) and rebranded under a new name and ticker. EyePoint gained Icon's Dexycu dexamethasone intraocular suspension 9%, which received FDA approval in...
BC Week In Review | Feb 23, 2018
Clinical News

FDA approves Icon Bioscience's Dexycu

Icon Bioscience Inc. (Sunnyvale, Calif.) said FDA approved an NDA for Dexycu dexamethasone intraocular suspension to treat inflammation associated with cataract surgery. Dexycu is a sustained-release formulation of dexamethasone delivered using Verisome technology. The company...
BC Week In Review | Aug 18, 2017
Clinical News

FDA accepts Icon's NDA for ophthalmic product Dexycu

In June, Icon Bioscience Inc. (Newark, Calif.) said FDA accepted for review an NDA for Dexycu (IBI-10090) to reduce inflammation after cataract surgery. Its PDUFA date is Feb. 12, 2018. The company expects approval of...
BC Week In Review | Apr 13, 2015
Clinical News

IBI-10090: Phase III data

A double-blind, U.S. Phase III trial in 394 patients undergoing cataract surgery showed that 342 and 517 ug IBI-10090 injected into the anterior chamber of the eye each met the primary endpoint of a greater...
BC Week In Review | Oct 13, 2014
Clinical News

IBI-10090: Phase III ongoing

Icon said it completed treatment of 390 patients undergoing cataract surgery in a double-blind, placebo-controlled, U.S. Phase III trial evaluating 2 dose levels of IBI-10090 injected into the anterior chamber of the eye. Icon Bioscience...
BC Week In Review | May 19, 2014
Clinical News

IBI-10090: Phase III started

In December, Icon began a double-blind, placebo-controlled, U.S. Phase III trial in 390 patients to evaluate 2 doses of IBI-10090. The company said more than half of the patients have been enrolled. Icon Bioscience Inc....
BC Extra | Aug 29, 2013
Financial News

Ophthalmic company Icon raises $14.9 million

Icon Bioscience Inc. (Sunnyvale, Calif.) raised $14.9 million in a venture round, according to an SEC filing. The company could not be reached for details. Icon's IBI-10090 is in a Phase II/III trial to treat...
BC Week In Review | Jan 11, 2010
Clinical News

IBI-10090: Phase II/III started

Icon Bioscience began a U.S. Phase II/III trial to evaluate a single injection of IBI-10090 in >200 patients. Icon Bioscience Inc. , Sunnyvale, Calif.   Product: IBI-10090   Business: Ophthalmic   Molecular target: NA   Description:...
Items per page:
1 - 8 of 8